Article Text

Download PDFPDF
Other full case
Ten-year follow-up after autologous stem cell transplantation of a patient with immunoglobulin light-chain (AL) amyloidosis with deposits in the heart, liver and gastrointestinal tract
  1. Marit Mejhert1,
  2. Robert Hast2,
  3. Benngt Sandstedt1,
  4. Izabella Janczewska3
  1. 1Department of Clinical Sciences, Ersta Hospital and Karolinska Institutet, Danderyd Hospital,Stockholm, Sweden
  2. 2Karolinska Institutet, Hematology Center, Karolinska University Hospital, Stockholm, Sweden
  3. 3Department of Clinical Sciences, Division of Internal Medicine, Karolinska Institutet, Stockholm, Sweden
  1. Correspondence to Dr Izabella Janczewska, izabella.janczewska{at}ds.se

Summary

The prognosis in amyloid light chain (AL)-amyloidosis and multiorgan involvement is poor, with a high-treatment-related mortality after high-dose melphalan and autologous stem cell transplantation (HDM/SCT). Some patients, however, might benefit from the therapy. We report a case of cardiac AL-amyloidosis with multiorgan involvement where the progressive cardiomyopathy was halted after successful treatment with HDM/SCT in 2001. The patient is in an excellent cardiac condition with a good quality of life, receiving treatment with angiotensinogen receptor blockers and a flexible diuretics regimen at follow-up after 10 years.

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Not obtained.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.